QR Kodea

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

Abstract Introduction Risankizumab (RZB) and deucravacitinib (DEU) are both approved for the treatment of moderate-to-severe psoriasis. Physicians value head-to-head comparisons between available therapies to make evidence-based treatment decisions. This study evaluates the safety and efficacy of RZ...

Deskribapen osoa

Gorde:
Egile Nagusiak: Nina Magnolo, Jennifer Soung, John Frew, Antonio Costanzo, Hiram Ruiz-Santiago, Kilian Eyerich, Mar Llamas-Velasco, Michael Bukhalo, Raja K. Sivamani, Angela Moore, Tianshuang Wu, Jiaheng Xie, Manish Patel, Doug Ashley, Blair Kaplan, Vassilis Stakias, Ramon Espaillat, Richard B. Warren
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Adis, Springer Healthcare 2026-05-01
Saila:Dermatology and Therapy
Gaiak:
Moderate psoriasis
Risankizumab
Systemic therapy
Biologics
Sarrera elektronikoa:https://doi.org/10.1007/s13555-026-01779-x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak